GLP-1 in Aesthetics: Compounding, Sourcing & Legal Status

The FDA maintains an active shortage declaration for both semaglutide and tirzepatide, which temporarily permits licensed pharmacies to compound these drugs under 21 CFR 503.504. This authority is not permanent and is subject to periodic review and potential revocation. Compounding is permitted only when the FDA determines that the shortage cannot be adequately supplied by FDA-approved products. Check the FDA's official Shortage List (fda.gov/drugs/drug-shortages) regularly; the status can change without advance notice. If the shortage is lifted, compounding authority evaporates immediately, and any compounded product becomes illegal to dispense. Practices cannot compound these drugs in-house; only state-licensed pharmacies can, and only under the shortage declaration. Verify your pharmacy partner's state licensing and DEA registration. Some states (e.g., California, Texas) have issued additional guidance or restrictions on GLP-1 compounding; check your state pharmacy board's website for local rules. The compounding pharmacy must maintain proper documentation and chain of custody.

You may dispense or administer compounded semaglutide or tirzepatide if sourced from a licensed pharmacy operating under the FDA shortage exception. You cannot manufacture, compound, or import these drugs yourself. The product must be dispensed with proper labeling (including "compounded" designation), patient counseling, and documentation. Prescribing is within scope for licensed physicians and, in many states, nurse practitioners and physician assistants under delegation agreements. Verify your state's scope-of-practice rules; some states restrict GLP-1 prescribing to physicians only. If you administer injections, ensure your staff are properly trained and credentialed. Document informed consent, including the fact that the product is compounded (not FDA-approved) and that off-label use for weight loss or body contouring is not an FDA-cleared indication. Maintain records of the pharmacy source, lot numbers, and expiration dates. Do not make disease-treatment claims; frame offerings as adjunctive to lifestyle modification or cosmetic body contouring.

Source only from state-licensed, DEA-registered pharmacies that explicitly operate under the FDA shortage declaration. Request documentation: state pharmacy license, DEA registration, and written confirmation that they are compounding under 21 CFR 503.504. Reputable compounding pharmacies (e.g., those accredited by the Pharmacy Compounding Accreditation Board, PCAB) are preferable. Red flags include: pharmacies that do not provide written documentation of their authority, offer pricing significantly below market (suggesting diversion or unlicensed sourcing), lack verifiable state licensing, or ship across state lines without proper licensing in the destination state. Never source from online retailers, overseas suppliers, or non-pharmacy entities. Verify the pharmacy's quality-assurance protocols: sterility testing, beyond-use dating, and adverse-event reporting. Request a certificate of analysis for each batch. Maintain a written agreement with your pharmacy partner that specifies their responsibility for regulatory compliance and your right to audit their records.

State medical boards, pharmacy boards, and attorneys general have begun enforcement actions against practices offering compounded GLP-1s without proper sourcing, documentation, or informed consent. Common violations include: dispensing without a valid prescription, failing to disclose that the product is compounded and off-label, making unsubstantiated weight-loss or health claims, and sourcing from unlicensed or unverified suppliers. Penalties range from warning letters to license suspension or revocation. Several states have issued guidance clarifying that GLP-1 compounding is permitted only under the FDA shortage declaration and only when dispensed by a licensed pharmacy. Practices have faced enforcement for operating as unlicensed pharmacies or making misleading marketing claims. Document your compliance: written policies, staff training records, informed-consent forms, pharmacy-sourcing agreements, and adverse-event logs. If a patient reports an adverse event, report it to the pharmacy and consider reporting to the FDA's MedWatch system. Stay informed of your state board's guidance; many post FAQs or advisory opinions on GLP-1 compounding.

Offering compounded GLP-1s carries clinical and regulatory liability. Standard medical-malpractice insurance may not cover compounded drugs; verify coverage with your carrier before offering these products. Compounded drugs lack the safety and efficacy data of FDA-approved products, and adverse events (injection-site reactions, pancreatitis, thyroid concerns) are your responsibility to manage and document. Obtain informed consent in writing, specifying that the product is compounded (not FDA-approved), that it is being used off-label, and that risks include those associated with GLP-1 use generally plus the additional risks of compounding (e.g., sterility, potency variability). Screen patients for contraindications: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe renal impairment, or acute pancreatitis. Maintain detailed clinical notes, including baseline weight, metabolic markers if obtained, and follow-up assessments. If you do not have the clinical expertise to manage GLP-1 therapy (dosing, titration, adverse-event recognition), do not offer it. Consider partnering with a physician who specializes in weight management or endocrinology.

The compounded GLP-1 market is a temporary workaround. Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) are expanding manufacturing capacity, and the FDA shortage declarations are expected to be lifted in the coming years. When that occurs, compounding authority ends. Some practices are positioning themselves to offer FDA-approved products (Wegovy, Zepbound) directly once supply stabilizes and reimbursement improves. Others are exiting the space. Regulatory scrutiny is intensifying: the FDA, FTC, and state boards are coordinating enforcement against unlicensed compounding and misleading marketing. The FTC has issued warnings about unsubstantiated weight-loss claims. If you are currently offering compounded GLP-1s, develop an exit strategy or transition plan. Monitor FDA guidance and your state board's enforcement activity. Do not assume the current legal environment will persist.

• Verify your pharmacy partner is state-licensed, DEA-registered, and operating under FDA shortage authority; request written documentation quarterly.
• Confirm your state's scope-of-practice rules for prescribing and administering GLP-1s; consult your state medical board if unclear.
• Obtain written informed consent from every patient, disclosing compounded status, off-label use, and risks.
• Screen patients for contraindications and document clinical justification for therapy.
• Maintain records: pharmacy sourcing, lot numbers, expiration dates, patient consent, clinical notes, and adverse events.
• Verify your malpractice insurance covers compounded drugs; if not, obtain a rider or decline to offer.
• Train staff on proper injection technique, adverse-event recognition, and patient counseling.
• Monitor FDA shortage list and state board guidance monthly; have a plan to discontinue if legal status changes.
• Report adverse events to the pharmacy and consider FDA MedWatch reporting.
• Do not make disease-treatment or unsubstantiated health claims in marketing; frame as cosmetic or adjunctive.